Print

Valeant Pharmaceuticals International (VRX) Completes Syndication of Incremental Term Loans  
6/15/2012 10:12:12 AM

MONTREAL, June 14, 2012 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today the successful syndication of $600 million of incremental term loans under its existing senior secured credit facilities to be used to fund repayment of amounts outstanding under its existing $275 million revolving facility and for general corporate purposes, including acquisitions. The incremental term loans will mature in 2019 and have terms that are similar to the Company's existing $600 million Term Loan B facility, with certain modifications. The facility closed on June 14, 2012.

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)

Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com

SOURCE Valeant Pharmaceuticals International, Inc.


//-->